

Carol Pollock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1037333/publications.pdf>

Version: 2024-02-01

125
papers

9,439
citations

94433

37
h-index

39675

94
g-index

128
all docs

128
docs citations

128
times ranked

10686
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDESCENCE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 361-373.	4.5	9
2	Preconception weight loss improves fertility and maternal outcomes in obese mice. <i>Journal of Endocrinology</i> , 2022, 253, 27-38.	2.6	8
3	Cost of End-of-Life Inpatient Encounters in Patients with Chronic Kidney Disease in the United States: A Report from the DISCOVER CKD Retrospective Cohort. <i>Advances in Therapy</i> , 2022, 39, 1432-1445.	2.9	3
4	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDESCENCE trial. <i>Diabetes and Metabolism</i> , 2022, 48, 101331.	2.9	5
5	Systematic review of intraoperative duplex scanning during renal transplantation. <i>Australasian Journal of Ultrasound in Medicine</i> , 2022, 25, 42-50.	0.6	3
6	Prior Cardiovascular Treatments—A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction. <i>Frontiers in Pharmacology</i> , 2022, 13, 834898.	3.5	1
7	How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 727-737.	2.9	17
8	Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDESCENCE Trial. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-12.	2.3	3
9	Diet Modification before or during Pregnancy on Maternal and Foetal Outcomes in Rodent Models of Maternal Obesity. <i>Nutrients</i> , 2022, 14, 2154.	4.1	4
10	Organ protection beyond glycaemic control with SGLT2 inhibitors. <i>Nature Reviews Nephrology</i> , 2021, 17, 223-224.	9.6	4
11	Use of sodium-glucose cotransporter2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 299-317.	4.4	20
12	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology—Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2021, 77, 255-263.	1.9	21
13	Sodium-glucose cotransporter2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 382-390.	4.4	40
14	Insights from CREDESCENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021, 99, 999-1009.	5.2	93
15	Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor. <i>Kidney International Reports</i> , 2021, 6, 284-295.	0.8	8
16	Epidemiology and burden of chronic kidney disease-associated pruritus. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, i1-i7.	2.9	27
17	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.	4.5	37
18	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDESCENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	2.7	30

#	ARTICLE	IF	CITATIONS
19	Methods and rationale of the DISCOVER CKD global observational study. CKJ: Clinical Kidney Journal, 2021, 14, 1570-1578.	2.9	11
20	Pre-Conception Weight Loss Improves Reproductive, Metabolic and Kidney Health in Obese Mice and Their Offspring. Journal of the Endocrine Society, 2021, 5, A322-A323.	0.2	1
21	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. Circulation, 2021, 143, 1735-1749.	1.6	60
22	MO516A STRUCTURED EXPERT ELICITATION TO INFORM AND VALIDATE MORTALITY EXTRAPOLATIONS FOR A COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	1
23	Mesenchymal Stem Cell-Derived Extracellular Vesicles to the Rescue of Renal Injury. International Journal of Molecular Sciences, 2021, 22, 6596.	4.1	37
24	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European Heart Journal, 2021, 42, 4891-4901.	2.2	80
25	Protocol for the Controlled evaluation of Angiotensin Receptor blockers for COVID-19 respiratory disease (CLARITY): a randomised controlled trial. Trials, 2021, 22, 573.	1.6	7
26	Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes. Advances in Chronic Kidney Disease, 2021, 28, 298-308.	1.4	6
27	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%. Circulation, 2020, 141, 407-410.	1.6	95
28	Orthostatic Renal Transplant Compression Following Weight Gain Leading to Acute Kidney Injury. Transplantation Proceedings, 2020, 52, 153-156.	0.6	0
29	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes and Endocrinology, 2020, 8, 903-914.	11.4	73
30	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 2925-2936.	6.1	82
31	Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m ² . Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1705-1714.	4.5	87
32	Prevalence, incidence and risk factors of diabetes in Australian adults aged >45 years: A cohort study using linked routinely-collected data. Journal of Clinical and Translational Endocrinology, 2020, 22, 100240.	1.4	6
33	RIPK3 blockade attenuates kidney fibrosis in a folic acid model of renal injury. FASEB Journal, 2020, 34, 10286-10298.	0.5	20
34	Therapy Escalation Following an Elevated HbA1c in Adults Aged 45 Years and Older Living With Diabetes in Australia: A Real-World Observational Analysis. Diabetes Care, 2020, 43, e185-e187.	8.6	1
35	Unusual cause of headache following renal transplantation. Nephrology, 2020, 25, 873-874.	1.6	0
36	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1128-1139.	6.1	106

#	ARTICLE	IF	CITATIONS
37	Non-invasive real-time imaging of reactive oxygen species (ROS) using auto-fluorescence multispectral imaging technique: A novel tool for redox biology. <i>Redox Biology</i> , 2020, 34, 101561.	9.0	33
38	Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy. <i>PLoS ONE</i> , 2020, 15, e0234617.	2.5	5
39	Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study. <i>Diabetes Care</i> , 2020, 43, 982-990.	8.6	15
40	RIPK3 blockade attenuates tubulointerstitial fibrosis in a mouse model of diabetic nephropathy. <i>Scientific Reports</i> , 2020, 10, 10458.	3.3	24
41	RIPK3: A New Player in Renal Fibrosis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 502.	3.7	12
42	The primary cilia in diabetic kidney disease: A tubulocentric view?. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 122, 105718.	2.8	4
43	EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study. <i>JMIR Research Protocols</i> , 2020, 9, e15646.	1.0	9
44	Risk Factors for Incident Kidney Disease in Older Adults: an Australian Prospective Populationâ€Based Study. <i>Internal Medicine Journal</i> , 2020, , .	0.8	3
45	Title is missing!. , 2020, 15, e0234617.		0
46	Title is missing!. , 2020, 15, e0234617.		0
47	Title is missing!. , 2020, 15, e0234617.		0
48	Title is missing!. , 2020, 15, e0234617.		0
49	Title is missing!. , 2020, 15, e0234617.		0
50	Title is missing!. , 2020, 15, e0234617.		0
51	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	1.6	211
52	MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update. <i>FASEB BioAdvances</i> , 2019, 1, 375-388.	2.4	25
53	Routine glucose assessment in the emergency department for detecting unrecognised diabetes: a cluster randomised trial. <i>Medical Journal of Australia</i> , 2019, 211, 454-459.	1.7	12
54	Intravenous amino acid therapy for kidney protection in cardiac surgery patients: A pilot randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 2356-2366.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 429-441.	11.4	137
56	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 37-47.	5.2	235
57	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 393, 1937-1947.	13.7	408
58	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.	27.0	3,760
59	Treatment strategy of end stage renal disease-related hyperparathyroidism before, during, and after the era of calcimimetics. <i>Surgery</i> , 2019, 165, 135-141.	1.9	7
60	SIRT1 Attenuates Kidney Disorders in Male Offspring Due to Maternal High-Fat Diet. <i>Nutrients</i> , 2019, 11, 146.	4.1	22
61	SIRT1 overexpression attenuates offspring metabolic and liver disorders as a result of maternal high-fat feeding. <i>Journal of Physiology</i> , 2019, 597, 467-480.	2.9	25
62	Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2018, 72, 62-74.	1.9	39
63	Drug repurposing in kidney disease. <i>Kidney International</i> , 2018, 94, 40-48.	5.2	41
64	Metformin attenuates folic acid induced renal fibrosis in mice. <i>Journal of Cellular Physiology</i> , 2018, 233, 7045-7054.	4.1	23
65	The role of toll-like receptors in diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 30-34.	2.0	25
66	SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018, 136, 23-31.	2.8	14
67	The authors reply. <i>Kidney International</i> , 2018, 94, 831.	5.2	1
68	SRT1720 attenuates obesity and insulin resistance but not liver damage in the offspring due to maternal and postnatal high-fat diet consumption. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E196-E203.	3.5	17
69	The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy. <i>PLoS ONE</i> , 2018, 13, e0192800.	2.5	15
70	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2017, 70, 464-475.	1.9	218
71	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet, The</i> , 2017, 390, 1888-1917.	13.7	662
72	Maternal high-fat diet induces metabolic stress response disorders in offspring hypothalamus. <i>Journal of Molecular Endocrinology</i> , 2017, 59, 81-92.	2.5	23

#	ARTICLE	IF	CITATIONS
73	Genetic and environmental risk factors for chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 88-106.	14.2	57
74	The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 130-137.	14.2	8
75	SIRT1 reduction is associated with sex-specific dysregulation of renal lipid metabolism and stress responses in offspring by maternal high-fat diet. <i>Scientific Reports</i> , 2017, 7, 8982.	3.3	28
76	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrologyâ€“Hemodialysis (SONG-HD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2017, 69, 97-107.	1.9	148
77	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017, 46, 462-472.	3.1	194
78	Maternal L-Carnitine Supplementation Improves Brain Health in Offspring from Cigarette Smoke Exposed Mothers. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 33.	2.9	23
79	Maternal Cigarette Smoke Exposure Worsens Neurological Outcomes in Adolescent Offspring with Hypoxic-Ischemic Injury. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 306.	2.9	22
80	Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. <i>BMC Cancer</i> , 2016, 16, 488.	2.6	78
81	Impact of maternal cigarette smoke exposure on brain inflammation and oxidative stress in male mice offspring. <i>Scientific Reports</i> , 2016, 6, 25881.	3.3	60
82	Impact of maternal cigarette smoke exposure on brain and kidney health outcomes in female offspring. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 1168-1176.	1.9	16
83	Long non-coding RNAsâ€“towards precision medicine in diabetic kidney disease?. <i>Clinical Science</i> , 2016, 130, 1599-1602.	4.3	15
84	Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. <i>Scientific Reports</i> , 2016, 6, 26428.	3.3	119
85	Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes. <i>Nephrology</i> , 2016, 21, 423-431.	1.6	55
86	Standardised outcomes in nephrology â€“ Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. <i>Trials</i> , 2015, 16, 364.	1.6	67
87	The Role of Dipeptidyl Peptidase â€“ 4 Inhibitors in Diabetic Kidney Disease. <i>Frontiers in Immunology</i> , 2015, 6, 443.	4.8	35
88	P-52â€“Delivering advance care planning in chronic kidney disease (CKD): The perspectives of healthcare providers. <i>BMJ Supportive and Palliative Care</i> , 2015, 5, A59.2-A59.	1.6	0
89	Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFâ€“ through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin. <i>PLoS ONE</i> , 2015, 10, e0141143.	2.5	24
90	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. <i>American Journal of Kidney Diseases</i> , 2015, 66, 212-222.	1.9	73

#	ARTICLE	IF	CITATIONS
91	Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial. <i>Intensive Care Medicine</i> , 2015, 41, 1197-1208.	8.2	146
92	Short term exendin-4 treatment reduces markers of metabolic disorders in female offspring of obese rat dams. <i>International Journal of Developmental Neuroscience</i> , 2015, 46, 67-75.	1.6	9
93	A Cationic-Independent Mannose 6-Phosphate Receptor Inhibitor (PXS64) Ameliorates Kidney Fibrosis by Inhibiting Activation of Transforming Growth Factor- β 1. <i>PLoS ONE</i> , 2015, 10, e0116888.	2.5	17
94	High Glucose Induces CCL20 in Proximal Tubular Cells via Activation of the KCa3.1 Channel. <i>PLoS ONE</i> , 2014, 9, e95173.	2.5	17
95	The Impact of Maternal Cigarette Smoke Exposure in a Rodent Model on Renal Development in the Offspring. <i>PLoS ONE</i> , 2014, 9, e103443.	2.5	36
96	Role of Toll-like receptors in diabetic nephropathy. <i>Clinical Science</i> , 2014, 126, 685-694.	4.3	63
97	SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. <i>Australasian Medical Journal</i> , 2014, 7, 405-415.	0.1	34
98	Fabry disease deposition mimicking a cardiac tumour and precipitating heart block. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 869-869.	1.2	0
99	KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 313-324.	0.7	44
100	Inhibition of KCa3.1 suppresses TGF- β 1 induced MCP-1 expression in human proximal tubular cells through Smad3, p38 and ERK1/2 signaling pathways. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 47, 1-10.	2.8	27
101	The Role of TLR2 and 4-Mediated Inflammatory Pathways in Endothelial Cells Exposed to High Glucose. <i>PLoS ONE</i> , 2014, 9, e108844.	2.5	91
102	Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 481-95.	0.5	21
103	Toward a bioartificial kidney: will embryonic stem cells be the answer?. <i>Kidney International</i> , 2013, 83, 543-545.	5.2	10
104	Semicarbazide-sensitive amine oxidase and kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F1637-F1644.	2.7	12
105	Sodium glucose cotransporter 2 and the diabetic kidney. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 113-119.	2.0	52
106	Combined Effects of PPAR β Agonists and Epidermal Growth Factor Receptor Inhibitors in Human Proximal Tubule Cells. <i>PPAR Research</i> , 2013, 2013, 1-8.	2.4	6
107	Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?. <i>PLoS ONE</i> , 2013, 8, e54442.	2.5	224
108	Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial. <i>PLoS ONE</i> , 2013, 8, e55807.	2.5	34

#	ARTICLE	IF	CITATIONS
109	Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. <i>Kidney International</i> , 2012, 81, 727-732.	5.2	92
110	Novel Treatments in Diabetic Nephropathy. <i>Current Hypertension Reviews</i> , 2012, 8, 71-78.	0.9	0
111	How do people with chronic kidney disease value cancer-related quality of life?. <i>Nephrology</i> , 2012, 17, 32-41.	1.6	16
112	Renal epidermal growth factor receptor: Its role in sodium and water homeostasis in diabetic nephropathy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2011, 38, 84-88.	1.9	23
113	Renal glucose transporters: novel targets for hyperglycemia management. <i>Nature Reviews Nephrology</i> , 2010, 6, 307-311.	9.6	57
114	Pure Red Cell Aplasia Induced by Erythropoiesis-Stimulating Agents. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 193-199.	4.5	83
115	Peritubular Ischemia Contributes More to Tubular Damage than Proteinuria in Immune-Mediated Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 290-297.	6.1	14
116	Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin) Tj ETQq0 0.0,rgBT /Oylock 10	6.7	12
117	Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2006, 26, 520-2.	2.3	98
118	Energy intake in predialysis patients. <i>Nephrology</i> , 2005, 10, S177-S179.	1.6	25
119	The development of encapsulating peritoneal sclerosis. <i>Peritoneal Dialysis International</i> , 2005, 25 Suppl 3, S113-4.	2.3	0
120	Albumin and Glucose Effects On Cell Growth Parameters, Albumin Uptake and Na ⁺ /H ⁺ -Exchanger Isoform 3 in OK Cells. <i>Cellular Physiology and Biochemistry</i> , 2003, 13, 199-206.	1.6	27
121	Primary focal sclerosing glomerulonephritis: A clinicopathological analysis. <i>Nephrology</i> , 1998, 4, 9-17.	1.6	5
122	Comparison of Simultaneous Renal Clearances of True Endogenous Creatinine and Subcutaneously Administered iothalamate in Man. <i>American Journal of Nephrology</i> , 1995, 15, 277-282.	3.1	7
123	EFFECT OF ATRIAL NATRIURETIC PEPTIDE ON CELLULAR ELEMENT CONCENTRATIONS IN RAT PROXIMAL TUBULES: EVIDENCE FOR INHIBITION OF THE SODIUM PUMP. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1994, 21, 775-780.	1.9	5
124	Dysmorphism of urinary red blood cells—Value in diagnosis. <i>Kidney International</i> , 1989, 36, 1045-1049.	5.2	61
125	Lead intoxication in industry. <i>Medical Journal of Australia</i> , 1987, 146, 113-113.	1.7	0